2024
Engineered heart tissue: Design considerations and the state of the art
Gokhan I, Blum T, Campbell S. Engineered heart tissue: Design considerations and the state of the art. Biophysics Reviews 2024, 5: 021308. PMID: 38912258, PMCID: PMC11192576, DOI: 10.1063/5.0202724.Peer-Reviewed Original ResearchContractile phenotypes of engineered heart tissues derived from hypertrophic cardiomyopathy patients lacking sarcomeric mutations
Rasheed Y, Young S, Halder S, Li X, Stendahl J, Campbell S. Contractile phenotypes of engineered heart tissues derived from hypertrophic cardiomyopathy patients lacking sarcomeric mutations. Biophysical Journal 2024, 123: 388a. DOI: 10.1016/j.bpj.2023.11.2357.Peer-Reviewed Original ResearchClassifying pathogenicity of TPM1 variants of unknown significance using in vitro and in silico approaches
Campbell S, Creso J, Firlar I, Halder S, Lehman W, Rynkiewicz M, Moore J. Classifying pathogenicity of TPM1 variants of unknown significance using in vitro and in silico approaches. Journal Of Cardiac Failure 2024, 30: s3. DOI: 10.1016/j.cardfail.2023.11.005.Peer-Reviewed Original ResearchHypertrophic cardiomyopathyUnknown significanceContractile forceOngoing clinical challengeFirst-degree relativesGenetic testing yieldSlowing of relaxationViral exposureContractile weaknessClinical challengeHypercontractile phenotypeHCM mutationsMyofilament activityHeart tissueMild phenotypeFurther studiesContractile behaviorSignificant increaseHEHTTesting yieldDCM mutationsMinimal effectVUSPathogenicityPhenotype
2023
Increased length-dependent activation of human engineered heart tissue after chronic α1A-adrenergic agonist treatment: testing a novel heart failure therapy
Rupert C, López J, Cortez-Toledo E, De la Cruz Cabrera O, Chesler N, Simpson P, Campbell S, Baker A. Increased length-dependent activation of human engineered heart tissue after chronic α1A-adrenergic agonist treatment: testing a novel heart failure therapy. AJP Heart And Circulatory Physiology 2023, 324: h293-h304. PMID: 36637971, PMCID: PMC9886349, DOI: 10.1152/ajpheart.00279.2022.Peer-Reviewed Original ResearchConceptsHuman heart failureHeart failureAR stimulationChronic stimulationLength-dependent activationVehicle treatmentHeart tissueAdrenergic receptorsHuman EHTsAnimal heart failure modelNovel heart failure therapiesHeart failure therapyHeart failure modelMultiple preclinical modelsFailure therapyAgonist treatmentSeparate control experimentsPreclinical modelsDrug washoutTherapeutic effectTranslational significanceHuman myocardiumBaseline testingRNA-seq analysisPig myocardium
2022
Physiological calcium combined with electrical pacing accelerates maturation of human engineered heart tissue
Shen S, Sewanan LR, Shao S, Halder SS, Stankey P, Li X, Campbell SG. Physiological calcium combined with electrical pacing accelerates maturation of human engineered heart tissue. Stem Cell Reports 2022, 17: 2037-2049. PMID: 35931080, PMCID: PMC9481907, DOI: 10.1016/j.stemcr.2022.07.006.Peer-Reviewed Original ResearchConceptsHuman-induced pluripotent stem cell-derived cardiomyocytesWide potential applicationsRegenerative medicineScalable platformElectrical pacingPotential applicationsForce-frequency behaviorCardiac troponin IPluripotent stem cell-derived cardiomyocytesStem cell-derived cardiomyocytesAdrenergic responseCell-derived cardiomyocytesFunctional maturationHiPSC-CM maturationTroponin IClinical researchTwitch kineticsHeart tissuePhysiological CaPacingPhysiological calciumApplicationsBasic researchRole of CaMaturationIncreased length-dependent activation of human engineered heart tissue after chronic treatment with alpha-1A-adrenergic agonist
Rupert C, Cortez-Toledo E, Lopez J, Chesler N, Simpson P, Campbell S, Baker A. Increased length-dependent activation of human engineered heart tissue after chronic treatment with alpha-1A-adrenergic agonist. Biophysical Journal 2022, 121: 397a-398a. DOI: 10.1016/j.bpj.2021.11.785.Peer-Reviewed Original Research